Literature DB >> 10986179

Achieving further glycemic control in type 2 diabetes mellitus.

G A Nichols1, H S Glauber, K Javor, J B Brown.   

Abstract

OBJECTIVES: To identify patients with type 2 diabetes mellitus who were in poor glycemic control and therapeutic adjustments that might improve control.
DESIGN: Using electronic pharmacy data, we assigned subjects to 1 of 4 therapeutic categories. We then identified patients within each category who did not meet the recommended standard of glycemic control (glycosylated hemoglobin [Hb A(1c)] <0. 08 [<8.0%]) and studied their therapetic regimens for possible improvements.
SUBJECTS: The subjects were 5,061 members of a large group-model health maintenance organization who had type 2 diabetes and 12 months of 1997 health plan eligibility. Main outcome measures The dosage of antihyperglycemic agents (sulfonylureas, metformin, and insulin) in relation to glycemic control as measured by the Hb A(1c).
RESULTS: A significant number (n = 1,570 [31.0%]) of persons with type 2 diabetes might improve their glycemic control with simple adjustments to their pharmacologic therapy.
CONCLUSION: Busy clinicians with heavy workloads can improve their management of diabetes by identifying patients whose glycemic control could be improved through a change in medication or simple adjustment in dosage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10986179      PMCID: PMC1071057          DOI: 10.1136/ewjm.173.3.175

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  8 in total

1.  New HEDIS means more information about HMOs.

Authors:  P L Grimaldi
Journal:  J Health Care Finance       Date:  1997

Review 2.  Oral hypoglycemic agents.

Authors:  J E Gerich
Journal:  N Engl J Med       Date:  1989-11-02       Impact factor: 91.245

3.  Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes.

Authors:  L C Groop; R Pelkonen; S Koskimies; G F Bottazzo; D Doniach
Journal:  Diabetes Care       Date:  1986 Mar-Apr       Impact factor: 19.112

4.  Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group.

Authors: 
Journal:  JAMA       Date:  1996-11-06       Impact factor: 56.272

5.  The progressive cost of complications in type 2 diabetes mellitus.

Authors:  J B Brown; K L Pedula; A W Bakst
Journal:  Arch Intern Med       Date:  1999-09-13

6.  Case-control study of 10 years of comprehensive diabetes care.

Authors:  J B Brown; G A Nichols; H S Glauber
Journal:  West J Med       Date:  2000-02

Review 7.  Organizing care for patients with chronic illness.

Authors:  E H Wagner; B T Austin; M Von Korff
Journal:  Milbank Q       Date:  1996       Impact factor: 4.911

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

  8 in total
  5 in total

Review 1.  Comparative health systems research among Kaiser Permanente and other integrated delivery systems: a systematic literature review.

Authors:  Jared Lane K Maeda; Karen M Lee; Michael Horberg
Journal:  Perm J       Date:  2014-06-09

2.  Comparison of demographic factors and cardiovascular risk factor control among U.S. adults with type 2 diabetes by insulin treatment classification.

Authors:  Kalina Wong; Diana Glovaci; Shaista Malik; Stanley S Franklin; Gail Wygant; Uchenna Iloeje; Hongjun Kan; Nathan D Wong
Journal:  J Diabetes Complications       Date:  2012-04-12       Impact factor: 2.852

3.  Drug titration patterns and HbA 1c levels in type 2 diabetes.

Authors:  J Ross Maclean; R H Chapman; C P Ferrufino; G Krishnarajah
Journal:  Int J Clin Pract       Date:  2009-07       Impact factor: 2.503

4.  Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy.

Authors:  Gregory A Nichols; Yuri H Koo; Sonali N Shah
Journal:  J Gen Intern Med       Date:  2007-04       Impact factor: 5.128

5.  Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures.

Authors:  Joel M Neutel; Cathy Zhao; Chetan S Karyekar
Journal:  Diabetes Ther       Date:  2013-07-24       Impact factor: 2.945

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.